Scott Morenstein Insider Profile
4 Followers
Scott Morenstein, Director at Madrigal Pharmaceuticals, holds 2.05M shares in Molecular Templates (Ticker: MTEMQ), holds 6.28K shares in Celator Pharmaceuticals (Ticker: CLPM), holds 17.86K shares in Madrigal Pharmaceuticals (Ticker: MDGL). Most recently, Scott Morenstein Bought ― shares of Molecular Templates on Nov 25, 2019 for an estimated value of $3.75M.
Scott Morenstein's Trading History
| MTEMQMolecular Templates | Nov 25, 2019 | ― | Informative Buy | 3.75M | $59.54K | |
| CLPMCelator Pharmaceuticals | Jul 12, 2016 | ― | Uninformative Sell | 31.62M | $189.82K | |
| MDGLMadrigal Pharmaceuticals | Jan 05, 2016 | Director | Uninformative Buy | ― | $7.63M |
You May Also Like
Scott Morenstein insider profile FAQ
What is the percentage of profitable transactions made by Scott Morenstein?
The percentage of profitable transactions made by Scott Morenstein is 50%.
What is the average return per transaction made by Scott Morenstein?
The average return per transaction made by Scott Morenstein is 3.20%.
What stocks does Scott Morenstein hold?
Scott Morenstein holds: MDGL, MTEMQ, CLPM stocks.
What was Scott Morenstein’s latest transaction?
Scott Morenstein’s latest transaction was an Informative Buy of $3.75M.
What was Scott Morenstein's most profitable transaction?
Scott Morenstein’s most profitable transaction was an Informative Buy of MTEMQ stock on September 27, 2018. The return on the trade was 23.90%.
What is Scott Morenstein's role in Madrigal Pharmaceuticals?
Scott Morenstein's role in Madrigal Pharmaceuticals is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.
TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.
